At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 21 enrolled
Drug / intervention
Stribilddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Switching From Atripla to Stribild Leads to Improvements in Central Nervous System Side Effects and Sleep Disturbances
In Brief
A Phase 4 clinical trial evaluating Stribild for HIV and 2 related conditions. Completed, enrolled 21 participants.
Detailed Summary
Switch patients from Atripla to Stribild will be evaluated to see if patients have less sleep disturbances.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV, AIDS, Sleep Disorders
Countries--
CollaboratorsGilead Sciences
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartFeb 2015
First PostedJun 2015
Primary CompletionDec 2015
Study CompletionJan 2016
TodayJul 2026
First PostedJun 22, 2015
Enrollment StartFeb 1, 2015
Primary CompletionDec 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.0 years ago
Interventions
Stribilddrug
Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.